Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY FE 1/20 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH and LH) release via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Also alters cervical mucus and endometrial lining to impair sperm penetration and implantation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
FDA-approved for prevention of pregnancy.
Prevention of pregnancy
One tablet orally once daily for 21 consecutive days followed by 7 days of placebo tablets.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: approximately 17 ± 5 hours (terminal); Norethindrone: approximately 8 ± 2 hours (terminal). Clinical context: Steady-state reached within 7-10 days; once-daily dosing maintains effective concentrations for contraceptive efficacy.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol is primarily metabolized via CYP3A4 hydroxylation and conjugation (glucuronidation/sulfation). Norethindrone is metabolized by reduction, hydroxylation, and conjugation, primarily via CYP3A4.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal (approximately 50-60% as metabolites, including glucuronide conjugates of ethinyl estradiol and norethindrone, and about 20% as unchanged norethindrone); Fecal (approximately 30-40% as metabolites); Biliary (minor, with enterohepatic circulation of ethinyl estradiol conjugates).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: approximately 97-98% bound to albumin (primarily) and sex hormone-binding globulin (SHBG); Norethindrone: approximately 93-95% bound to albumin and SHBG.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: approximately 2-4 L/kg; Norethindrone: approximately 4-6 L/kg. Clinical meaning: Extensive tissue distribution, with accumulation in adipose tissue and reproductive organs.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: Ethinyl estradiol ~40-45% (first-pass metabolism); Norethindrone ~60-65% (first-pass metabolism).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to risk of hyperkalemia.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in patients with active liver disease or Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults: one tablet orally once daily for 21 days, then 7 days of placebo.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. No specific geriatric dosing adjustments; consider increased risk of thromboembolic events and cardiovascular disease.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction, thromboembolism) from combination oral contraceptives. Risk increases with age (>35 years) and heavy smoking (≥15 cigarettes/day). Women who are >35 years old and smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Increased risk of thrombotic disorders including venous thromboembolism, stroke, and myocardial infarction.,Discontinue if sudden partial or complete loss of vision or onset of proptosis, diplopia, migraine.,Elevated blood pressure; use caution in hypertension.,Gallbladder disease; increased risk of gallstones.,Carbohydrate and lipid metabolism effects; use caution in diabetes and hyperlipidemia.,Hepatic neoplasia; discontinue if jaundice or liver dysfunction.,Chloasma; avoid sun or UV exposure.,Bleeding irregularities; may cause breakthrough bleeding and spotting.,Possible decreased efficacy with concomitant enzyme-inducing drugs.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history).,Cerebrovascular or coronary artery disease (current or history).,Known or suspected breast carcinoma or estrogen-dependent neoplasia.,Undiagnosed abnormal genital bleeding.,Pregnancy (known or suspected).,Benign or malignant liver tumor (active or history).,Active liver disease with abnormal liver function.,Hypersensitivity to any component.,Age >35 years with cigarette smoking.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions. Grapefruit juice may increase estrogen levels; avoid excessive consumption. St. John's Wort may reduce efficacy. Consistent intake with or without food is recommended to maintain steady-state levels.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester: No increased risk of major birth defects in large epidemiological studies. Second and third trimesters: Use is not recommended due to potential adverse effects on fetal development, including possible estrogenic effects and association with congenital anomalies in animal studies. Fetal risk cannot be ruled out.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in breast milk in small amounts. Estrogen and progestin levels may affect milk composition and reduce milk production. M/P ratio not reported; use caution, especially in the immediate postpartum period. Avoid use in breastfeeding women if possible.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustment established; use is contraindicated during pregnancy. If inadvertent exposure occurs, discontinue immediately. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) do not warrant dose adjustment because the drug is contraindicated.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Contains ethinyl estradiol 20 mcg and norethindrone 1 mg. Consider lower estrogen dose for patients with estrogen-sensitive migraines or history of thromboembolism. Monitor for breakthrough bleeding, especially in first 3 cycles. CYP3A4 inducers like rifampin may reduce efficacy. Check pregnancy test before initiating if delayed menses. Use with caution in patients with hypertriglyceridemia.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time, in the order listed on the pack.,If you miss a dose, take it as soon as remembered; if more than 24 hours late, use backup contraception.,Common side effects: nausea, breast tenderness, spotting, and headache.,Report signs of blood clots: sudden leg pain, chest pain, or shortness of breath.,Smoking increases risk of serious cardiovascular side effects, especially if over 35 years old.,Antibiotics (except rifampin) do not reduce effectiveness; inform your provider about all medications.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HAILEY FE 1/20 vs ALYACEN 7/7/7, answered by our medical review team.
HAILEY FE 1/20 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH and LH) release via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Also alters cervical mucus and endometrial lining to impair sperm penetration and implantation.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HAILEY FE 1/20 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HAILEY FE 1/20 is: One tablet orally once daily for 21 consecutive days followed by 7 days of placebo tablets.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HAILEY FE 1/20 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HAILEY FE 1/20 is classified as Category C. First trimester: No increased risk of major birth defects in large epidemiological studies. Second and third trimesters: Use is not recommended due to potential adverse effects on . ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.